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Serological and primary structural analyses of murine monoclonal antibodies have 
shown that several idiotypes (Id) that are highly cross-reactive within an inbred strain 
comprise a  family of closely related, but nonidentical, antibody molecules (1-11).  In 
the  case of A/J  anti-p-azophenylarsonate  (Ar) 1 antibodies,  serological evidence for 
idiotypic heterogeneity of cross-reactive idiotype  (CRI) ÷ hybridoma products  (HP) 
includes the wide quantitative variation in their inhibitory capacity in the standard 
radioimmune  assay  for Id.  The  amounts  of such  HP  required  to  displace  50%  of 
labeled  specifically purified  A/J  anti-Ar  from  its  rabbit  anti-Id  antibodies  varied 
between 9 and 3,200 ng (6, 7). In addition, anti-Id antisera prepared against individual 
CRI  + HP revealed the presence of private idiotypic determinants that were not found 
in other CRI  ÷ HP; some of these determinants were, however, present in A/J anti-Ar 
immune serum (5-7). 
To date, structural correlates of the Ar Id have not been fully established. However, 
it has been shown that the third complementarity-determining region and J  segments 
of both the heavy and light chains of the CRI  ÷ HP 93G7 are very similar, although 
not  identical  to the corresponding sequences in pooled CRI  ÷ A/J serum antibodies 
(L. J.  McCumber,  P.  Estess, M.  Siegelman, and J.  D. Capra. Manuscript  in prepa- 
ration.). 
We present data here that indicate that most CRI  + HP possess at least one idiotypic 
determinant that is highly conserved. This was demonstrated by using anti-Id against 
one HP, with a second HP as the labeled ligand. Such a procedure, originally used in 
studies of human cold agglutinins and antiglobulins (12,  13), is designed to minimize 
the role of private idiotypic determinants  (12-14);  i.e.,  it  is anticipated  that such a 
system will primarily measure shared idiotypic determinants. With two such heterol- 
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ogous  systems,  it  was  found  that  the  majority  of  CRI +  HP  are  quantitatively 
equivalent to one another with respect to their inhibitory capacities, indicating they 
share one or more closely related public idiotypic determinant(s). Also, the binding of 
anti-Id mediated by such public determinants was almost completely inhibitable by 
hapten,  indicating that  these  determinants  are associated with  the  hapten-binding 
site. 
Materials and  Methods 
Preparation of Hybridomas That Secreted Anti-At Antibodies.  Hybridomas that  secreted mono- 
clonal anti-Ar antibodies were generated as previously described (4-6). In brief, A/J mice were 
immunized intraperitoneally with 500/~g of Keyhole limpet hemocyanin (KLH)-Ar emulsified 
in complete Freund's adjuvant. The animals were challenged intravenously 8 wk later with 100 
/~g of KLH-Ar in saline, and spleens were removed 4 d  afterward for fusion.  1 ×  10  s splenic 
leukocytes  and  1  ×  10  v nonsecreting  Sp2/0-Agl4  tumor  cells  (15)  were  fused  with  33% 
polyethylene glycol (PEG-1000; J, T.  Baker Chemical Co., Phillipsburg, N. J.).  Hybrid cells 
were  selected  in  medium  that  contained  hypoxanthine,  thymidine,  and  aminopterin,  as 
described by Littlefield (16).  Culture  supernates were tested  for anti-Ar activity on  bovine 
serum albumin (BSA)-Ar-coated polyvinyl microtiter plates by the method of Klinman et al. 
(17), The bound antibodies were quantitated by measuring the uptake of 12~I-labeled specifically 
purified rabbit anti-mouse Fab. Selected cultures that secreted anti-Ar antibodies were cloned 
either in soft agarose or by limiting dilution. Approximately 25% of anti-Ar HP were CRI  +. An 
HP was defined as CRI  ÷ if it caused at least 50% displacement of the ligand (labeled serum 
anti-Ar antibody) in the conventional assay for CRI (18).  17 HP, of which 14 were CRI  +, were 
used  in  this study.  13  of the  hybrid  lines arose  from  a  single mouse  (6),  and  the  other 4 
originated from two other mice (4, 5). Each hybrid was derived from a separate culture well 
and therefore represents the product of an independent fusion event. 
Isolation of Monoclonal Anti-At  Antibodies.  Ascites fluids  that  contained  large  amounts  of 
hybridoma antibody were generated by injecting  1-5  ×  106 hybrid cells into the peritoneal 
cavity of Pristane (Aldrich Chemical Co., Inc., Milwaukee, Wis.) -primed (BALB/c ×  A/J)F1 
mice (19). Anti-Ar antibodies were specifically purified by affinity chromatography (20) on a 
column of bovine gamma giobulin-Ar coupled to Sepharose 4B. Bound antibodies were eluted 
from the column with 0.5 M sodium Ar, pH 8.0.  Each HP was purified on a separate column 
and dialyzed for 1 wk against multiple changes of buffer to remove hapten. Each protein was 
homogeneous by the criteria of disc electrophoresis and sodium dodecyl sulfate-polyacrylamide 
gel electrophoresis under reducing conditions. Four HP were tested and found to be homoge- 
neous by the criterion of amino-terminal amino acid sequence analysis (5, 6). 
Anti-Id  Antisera.  Anti-Id antisera  were  prepared  in  rabbits  by  injections of specifically 
purified A/J anti-Ar antibodies or purified HP (6, 18). The antisera were adsorbed by successive 
passage over two columns of Sepharose 4B to which a crude globulin fraction of normal A/J 
serum had been conjugated by using cyanogen bromide (21). The anti-Id antisera against HP 
were additionally adsorbed with the BALB/c myeioma protein MOPC-21  (IgGl~) coupled to 
Sepharose 4B. All precipitating activity against normal mouse globulin was lost after passage 
over the first column. Rabbit anti-Id antibodies against the myeloma protein TEPC  15, which 
binds phosphorylcholine, were  the gift of Dr.  Alan R.  Brown,  Rosensteil  Research Center, 
Brandeis University, Waltham, Mass. 
Assays for Id.  Serological assays for idiotypic determinants expressed on  various anti-Ar 
antibodies were performed as previously described (6, 18). HP and affinity-purified serum anti- 
Ar antibodies were radiolabeled with carrier-free Na[~25I] (Amersham Corp., Arlington Heights, 
Ill.) by the chloramine T method (22). Binding assays used 10 ng of 125I-labeled ligand (affinity- 
purified HP or A/J serum anti-Ar antibody) and slightly less than an equivalent amount  of 
anti-Id antiserum.  Each assay was carried out  in the presence of 20-25 pl of normal mouse 
serum  (that contained ~80-100/~g of mouse immunoglobulin).  Rabbit anti-ovalbumin was 
also added to each mixture to keep the amount of rabbit immunoglobulin constant. Id-anti-Id 
complexes were precipitated by the addition of a slight excess of goat anti-rabbit Fc that had 
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and  overnight  at  4°C.  Precipitates  and  supernates  were separated  and  counted in  a  three- 
channel  Packard  22  gamma scintillation  spectrometer  (Packard  Instrument  Co., Inc., Downers 
Grove,  I11.). [  Na]CI was included  in  each  reaction  mixture  to permit  quantitation  of the 
amount  of supernate  that  remained  in  the pellet;  this eliminated  the necessity for washing 
~recipitates. The percentage of 125I-labeled ligand in each precipitate was calculated from the 
51  and  22Na counts  in  both  precipitate  and  supernate.  The  presence of the  Id  in  various 
unlabeled HP or in serum anti-Ar was quantitated through the capacity of the Id to inhibit the 
binding of the labeled ligand by the anti-Id antibodies. Varying amounts of the test  samples 
were incubated with anti-Id for 30 min at 37°C before the addition of the labeled ligand. Id- 
binding kassays for protein  TEPC  15  were carried  out  as  described  above.  In addition  the 
reaction mixture also contained 100 pg of the myeloma protein MOPC 460 (IgA, •). 
Haptens.  Phosphorylcholine chloride was obtained  from Sigma Chemical Co., St.  Louis, 
Mo. p-Aminobenzenearsonic acid (Eastman Kodak Co., Rochester, N. Y.) was recrystallized 
twice  from hot  water,  m-Azobenzene-p'-arsonate-3-(p-hydroxyphenyl)-propionic  acid  (ABA- 
HPP)  was synthesized by the reaction of the diazonium salt of p-aminobenzenearsonic acid 
with 3-(p-hydroxyphenyl)-propionic acid according to the method of Tabachnick and Sobotka 
(23). The resulting orange compound was further purified by chromatography on Sephadex G- 
15 in 0.05  M  (NH4)2CO3. Its purity was assessed  by thin-layer chromatography on silica  gel 
plates. 
Results 
The purpose of these experiments  was to serologically define the  public idiotypic 
determinants  responsible for the reactivity shared among many A/J anti-Ar HP and 
A/J  serum  anti-Ar antibodies.  Previous experiments  have demonstrated  that  CRI  + 
HP  that  differ with  respect  to primary structure  and  that  possess  private  idiotypic 
specificities are able to inhibit the reaction between rabbit anti-Id and serum anti-Ar 
antibodies  (4-7).  This indicates the existence of at  least one public or cross-reacting 
idiotypic determinant.  However, the amounts  of various  HP required  to cause  50% 
inhibition  in the assay vary markedly  (5, 6). 
To study the shared idiotypic determinants, an inhibition assay system was designed 
that, although allowing the measurement of public determinants,  minimized the role 
of the private determinants  (12-14). This was accomplished by using anti-Id antibod- 
ies directed to one HP with a  different CRI+-labeled HP as ligand. The two systems 
investigated  were:  (a)  rabbit  anti-idiotypic  antibodies  directed  against  HP  R16.7 
[anti-Id(R16.7)]  reacting  with  125I-labeled  HP  R10.8,  and  (b)  rabbit  anti-idiotypic 
antibodies directed against HP 93G7 [anti-Id(93G7)]reacting with labeled HP 121D7. 
The direct binding curves for these two interactions are shown in Fig. 1. Also presented 
are  the  autologous binding  curves:  anti-Id(R16.7)  reacting  with  labeled  HP  R16.7 
and anti-Id(93G7)  reacting with labeled  HP 93G7. It is evident  that the amounts of 
anti-Id  required  to  bind  the  heterologous  HP  were  somewhat  greater  than  the 
amounts required  in the autologous interactions.  However, the ratios are only of the 
order of 2 or 3 to 1. The differences in amounts required are not unexpected and. can 
be  accounted  for  by  the  presence  of antibodies  to  private  determinants  that  are 
operative in the autologous, but not in the heterologous, interactions. Any remaining 
difference  must  be  quite  small,  suggesting  that  binding  affinities  for  the  public 
determinants of the autologous and heterologous proteins are very similar. 
Inhibition of the Interaction of Anti-ld(R16.7)  with 125I-labeled HP RlO.8.  The data in 
Table I  show the  inhibitory capacities of a  number of unlabeled  anti-Ar HP in this 
system.  Included  in  the  table  are  14  HP that  are CRI  + and  3  that  are CRI-.  Also 
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FI~.  1.  Binding of 10 ng of 125I-labeled specifically  purified HP to autologous and heterolognus 
rabbit anti-Id antisera.  Id-anti-ld complexes  were precipitated with excess goat anti-rabbit Fc. C), 
HP R16.7  and anti-Id(Rl6.7); Q, HP R10.8  and anti-ld(R16.7);  /X, HP 93G7 and anti-Id(93G7); 
A, HP 121D7 and anti-Id(93G7). 
TABLE  I 
Inhibition by Unlabeled  HP of Binding of dnti-Id Antibodies to Heterologous Labeled HP* 
Unlabeled inhibitor 
Nanograms required for 50% inhibition 
Anti-Id against:  R 16.7  93G 7  Anti-Ar~ 
'25I-labeled ligand:  R 10.8  121 D7  Anti-Ar 
Serum anti-Ar  15 (100)§  11 (100)  l I (97) 
R16.7  (G1)  12 (100)  8 (97)  9 (94) 
93G7 (GI)  7 (100)  9 (99)  12 (90) 
R20.4  (GZb)  10 (92)  8 (92)  14 (86) 
R26.5  (G3)  12 (88)  10 (99)  17 (85) 
R13.4 (G3)  13 (100)  14 (97)  21  (87) 
RI0.8 (G2a)  8 (100)  7 (90)  180 (60) 
R23.2  (G2b)  5 (100)  7 (91)  200 (66) 
R9.3 (G2b)  9 (100)  10 (90)  300 (65) 
121D7 (G1)  17 (88)  16 (100)  300 (71) 
R17.5  (G2b)  7 (100)  7 (91)  460 (63) 
R24.6 (G2a)  6 (100)  7 (93)  1,800 (52) 
123E6 (G1)  >2,000 (35)  >2,000 (19)  1,900 (51) 
124El  (G1)  1,900 (51)  >2,000 (44)  2,900 (47) 
R22.4  (G2a)  6 (100)  7 (92)  3,200 (49) 
R18.1111 (G3)  >2,000 (0)  >2,000 (~2)  >2,000 (20) 
R19.911 (G2b)  >2,000 (4)  >2,000 (10)  >2,000 (15) 
R21.1011 (Gl)  >2,000 (0)  >2,000 (7)  >2,000 (6) 
* Each test utilized 10 ng of 125I-labeled ligand and slightly less than an equivalent amount of rabbit anti- 
Id. Immune complexes were precipitated by goat anti-rabbit Fc. 
Data in the last column are from reference 6. 
§ The percent inhibition by 2,000 ng is in parentheses. 
]] Anti-Ar HP lacking the major CRI. 
inhibitor.  The  data  are  expressed  as  nanograms  of protein  required  to  cause  50% 
inhibition in the radioimmune  assay. Also included, in parentheses,  are the values for 
percentage  inhibition obtained with a  large excess (2,000  ng)  of inhibitor. 
It  is evident  that  12  of the  14  CRI +  HP  were  very similar  to one  another  and  to 
serum anti-Ar antibodies in their quantitative inhibitory capacities in this system. For 
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ng. As shown in the last column of Table I, these HP varied widely in their inhibitory 
capacities  in  the  conventional  idiotypic  system  (rabbit  anti-idiotypic  antibodies 
directed  against  A/J  serum  anti-Ar  antibodies  [anti-ID(D)]reacting  with  labeled 
serum antibodies). The amounts required for 50% inhibition in the latter assay varied 
from 9 to 3,200 ng. 
2 of the 14 CRI  + HP, 123E6 and 124E 1, were weak inhibitors of the binding of HP 
R10.8 by anti-Id(R16.7). These two HP are also very poor inhibitors in the conven- 
tional assay (Table I, last column). 
Inhibition  of the Interaction of Anti-Id(93G7)  with IznI-labeled HP 121D7.  The results 
obtained in this system (Table I) are very similar to those already discussed. Again 12 
of the  14  HP, with  the  same two exceptions, were  very similar  in  their  inhibitory 
capacities  in  terms  of nanograms of protein  required  for  50%  inhibition  and  the 
degree of inhibition by 2,000 ng of protein. Serum anti-Ar was similar in its inhibitory 
capacity to the  12 strongly inhibitory HP. 
The  results  obtained  in  both  systems  when  very  large  amounts  (2,000  ng)  of 
unlabeled HP were tested as inhibitors are also informative. In both systems the same 
12 CRI  + HP, as well  as serum  anti-Ar, caused almost complete displacement  (88- 
100%) of the labeled ligand. Again these results stand in contrast to the data obtained 
in the anti-Id(D) vs. anti-Ar system (Table I, last column) in which most of the CRI  + 
HP were incapable of causing complete inhibition when 2,000 ng were tested. 
Effects  of Haptens  of Id-anti-Id Interactions.  The data in Table II show the effects of 
haptens  on  several  Id-binding  reactions.  The  haptens  tested  comprised  two  para 
derivatives of benzenearsonate (ABA-HPP and p-aminobenzenearsonic acid) and, as 
a control, phosphorylcholine. Each hapten was also tested for its inhibitory effect on 
the binding of myeloma protein TEPC  15,  which combines specifically with  phos- 
phoryleholine, to its rabbit anti-idiotypic antibodies. 
The data of  principal interest are those involving the heterologous binding reactions: 
anti-Id(R16.7)  reacting  with  HP  R10.8  and  anti-Id(93G7)  interacting  with  HP 
121D7.  These  cross-interactions  would  be  expected  to  principally  involve  public 
idiotypic determinants.  In the tWO systems the compound ABA-HPP caused 84 and 
88% inhibition, respectively, at a final concentration of 10 mM, indicating that a very 
TABLE II 
Inhibition by Haptens of Binding of Anti-Id Antibodies to Autologous and Heterologous HP 
Percent inhibition of binding; hapten 
p-Aminoben-  Phos- 
Anti-Id against  125I-labeled  ligand  ABA-HPP  zenearsonic  phoryl- 
acid  choline 
1"  5  10  5  10  20  20 
R16.7  RI0.8  69  80  84  39  49  58  0 
R16.7  R16.7  77  87  91  39  46  54  0 
93G7  121D7  82  87  88  43  50  56  0 
93G7  93G7  30  37  43  15  19  22  0 
Anti-Ar~:  Anti-Ar  66  79  83  27  32  41  0 
TEPC 15  TEPC 15  0  0  55 
* Final hapten concentrations in the reaction mixtures (mM). 
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large  fraction of the anti-Id  antibodies recognize determinants at or very near the 
binding sites of the ligands.  The smaller hapten, p-aminobenzenearsonic acid  was 
inhibitory in both systems but the degree of inhibition at a concentration of 20 mM 
was  less  (58  and  56%,  respectively). Phosphorylcholine was  noninhibitory in  both 
systems, although, as expected (24), it caused significant inhibition of the binding of 
the myeloma protein TEPC 15 to the autologous anti-Id. 
We also investigated the effects of haptens on the autologous systems (HP R16.7, 
HP  93G7,  and  serum  anti-Ar  reacting  with  their  respective  autologous  anti-Id 
antibodies). The degree of inhibition by ABA-HPP in the R16.7 and serum anti'-Ar 
systems was very high (91 and 83%), but it was considerably lower in the case of anti- 
Id(93GT)  reacting with  HP 93G7  (43%  at  10 mM).  In each system the single-ring 
compound, p-aminobenzenearsonic acid, inhibited significantly, but not as well as the 
two-ring compound, ABA-HPP. Again, phosphorycholine was noninhibitory. 
As an additional control, the two phenylarsonate derivates were also tested for their 
inhibitory effects in the anti-Id against TEPC 15-TEPC  15 ligand system (Table II). 
In each case, no inhibition was observed. 
Discussion 
Our results bear on the serological relationships among a group of anti-Ar HP that 
express the major CRI but also show individual variation. The criterion for possession 
of the major idiotypic determinant(s) is the capacity to cause 50% displacement of the 
labeled ligand  (purified A/J serum anti-At)  in the conventional radioimmune assay 
for Id. This degreeof inhibition has not been seen with antibodies other than anti-Ar 
and cannot be achieved with the anti-Ar antibodies of many other strains (25) or with 
anti-Ar  antibodies  from A/J  mice that  have  been  immunologically suppressed  by 
inoculation of anti-Id before immunization (26).  The individual structural variation 
of HP has been established by amino acid sequence analysis and by the presence of 
private idiotypic determinants (4-9)  (L. J. McCumber, P. Estess, M. Siegelman, and 
J. D. Capra. Manuscript in preparation.). Such determinants are revealed when anti- 
Id antibodies are prepared against an individual HP. Many CRI  + HP are relatively 
poor inhibitors of the binding of an  anti-Id  antibody to its autologous, CRI  + HP. 
Some, but  not all,  private determinants are found in  appreciable concentration in 
A/J anti-Ar sera. 
These  experiments  were  designed  to permit  analysis  of  the  shared  or  public 
determinant (s). Anti-Id antibodies against one HP were allowed to react with another, 
125I-labeled CRI + HP. This procedure should minimize the role of private idiotypic 
determinants. Such a procedure was originally used in human Id systems by Williams 
et al. (12) and Kunkel et al. (13) who first described the phenomenon of cross-idiotypic 
specificity.  Two  cross-idiotypic systems  were  investigated:  anti-Id(R16.7)  reacting 
with labeled HP RI0.8 and anti-Id(93G7) reacting with labeled HP 121D7. A panel 
of 14 unlabeled CRI  ÷ HP were tested as inhibitors of binding of the labeled ligand in 
each system, and 3 CRI- HP's were used as controls. The results obtained in the two 
systems were virtually identical.  12 of the 14 HP were very strong inhibitors, and the 
amounts of HP required for 50% inhibition varied over a narrow range. When 2,000 
ng were tested  as  inhibitor,  each of these  12  HP  caused  88-100%  inhibition.  The 
results were in marked contrast with the wide variation in inhibitory capacity seen in 
the conventional system, in which anti-Id(D) reacts with 125I-labeled serum anti-At. E. LAMOYI, P.  ESTESS, J.  D. CAPRA, AND A.  NISONOFF  709 
The results  indicate that  at  least one cross-reactive idiotypic determinant  is highly 
conserved and, by serological criteria, is virtually identical in  12 of the  14 CRI ÷ HP 
studied. The large variation in inhibitory capacities in the conventional assay must be 
attributed to microheterogeneity with respect to shared idiotypic determinants other 
than the conserved determinant identified by the cross-idiotypic assays. The HP may 
differ with respect to the number of such determinants they possess or with respect to 
their binding affinities for the anti-Id antibody. 
2 of the  14 CRI  ÷ HP were exceptional in that they were relatively poor inhibitors 
in the two systems designed to test for public determinants. These two proteins, 123E6 
and  124E1, were also very poor inhibitors in the conventional [D-(anti-Ar antibody 
possessing CRI of A/J strain mice) anti-Id(D)] assay.  However, proteins R24.6 and 
R22.4,  which  were  also  very weak  inhibitors  in  the  conventional assay  (Table  I, 
column  4),  were  very strong  inhibitors  in  the  assays  for  cross-idiotypy  (Table  I, 
columns 2 and 3).  It should be noted that proteins  123E6 and  124E1  can be bound 
almost completely by anti-Id(D), as shown by the inhibition of their binding to BSA- 
Ar-coated plates by anti-Id. The fact that they are weak inhibitors may be a result of 
either a deficiency in the number of public idiotypic determinants or of a structural 
alteration of the public determinants such that they interact with the anti-idiotypic 
antibodies with lower affinity. 
Thus,  the observation that  proteins  123E6 and  124E1  are poor inhibitors  in  the 
assay for cross-idiotypy suggests that public determinants can also exhibit microheter- 
ogeneity. However, the conservation of the determinants in  12 of the HP indicates 
that this variation is of secondary importance as compared to the variations reflected 
by the presence of the private idiotypic determinants. 
The effects of haptens on the two cross-Id systems studied indicate that the public 
determinants are localized in the region of the hapten-binding site. In both systems, 
the hapten ABA-HPP caused at least 84% inhibition of binding, p-Aminobenzenear- 
sonic acid  was  somewhat  less  effective, causing 56  and  58%  inhibition  in  the  two 
systems  at  a  concentration  of 20  mM.  The  difference in  effectiveness of the  two 
haptens  may  be  a  result  of a  difference in  affinities  or  size  (27).  If affinity  is  a 
significant  factor,  it  is  possible  that  ABA-HPP  would  cause  100%  inhibition  if a 
sufficiently high  concentration  were  used;  i.e.,  that  the  public  determinant(s)  are 
entirely associated with the region of the combining site. 
The above results  on  hapten  inhibition  contrast  with  the  data  obtained  in  the 
autologous system: HP 93G7 reacting with anti-Id(93G7).  In this system, only 43% 
inhibition  by  ABA-HPP  was  achieved.  This  suggests  that  the  anti-Id  antibodies 
prepared against HP 93G7 recognize determinants outside the combining site as well 
as site-related determinants. Anti-Id(R 16.7), in contrast, interacts almost entirely with 
site-related determinants on  the autologous protein,  liP  R16.7.  The interaction of 
anti-Id(D) with serum anti-Ar antibodies was inhibited to the extent of  83%, indicating 
that nearly all of the anti-Id recognized determinants near the hapten-binding site. 
Elucidation of the genetic control of this family of cross-reactive Id should be of 
great interest. Serological, as well as amino acid sequence, analyses suggests that the 
family may be very heterogeneous. On  the other hand, our data would lead to the 
prediction that there is a substantial portion of the amino acid sequence, at least in 
hypervariable regions, that is conserved. How heterogeneity is generated on a similar 
background, either through evolution of germ line genes or somatic mutation, may be 710  CONSERVED  CROSS-REACTIVE  IDIOTYPIC DETERMINANTS 
revealed by further amino acid sequence analyses and by studies at the level of DNA. 
Summary 
It has been shown that A/J anti-p-azophenylarsonate antibodies that share a major 
cross-reactive idiotype  (CRI)  comprise a  family of closely related,  but  nonidentical, 
molecules.  Our  results  demonstrate  that  12  of 14  monoclonal  hybridoma  products 
that  express  the  CRI  have  in  common  at  least  one  highly  conserved  idiotypic 
determinant.  It is proposed that this reflects conservation of a  portion of the amino 
acid  sequence,  presumably  in  hypervariable  regions.  That  the  conserved  determi- 
nant(s)  are located in the region of the hapten-binding site is indicated by the ability 
of haptens  to inhibit  idiotype-anti-idiotype  interactions  involving the  conserved, or 
public determinants. 
Received for publication  22 May  1980. 
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